4-Amino-1,2,5-oxadiazole-3-carboxylic acid → HCID 86636215, 화합물

HRID 541694

반응식

HRID 541694 반응식
[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].[F:8][C:9]([F:14])([F:13])[C:10]([OH:12])=[O:11].[Cl:15][C:16]1[CH:17]=[N:18][C:19]2[NH:20][C:21]3[CH:22]=[N:23][CH:24]=[C:25]([CH:47]=3)[CH2:26][CH2:27][C:28]3[CH:36]=[C:32]([NH:33][C:34]=1[N:35]=2)[CH:31]=[CH:30][C:29]=3[NH:37][C:38](=[O:46])[CH2:39][CH:40]1[CH2:45][CH2:44][NH:43][CH2:42][CH2:41]1.[NH2:48][C:49]1[C:50]([C:54](O)=[O:55])=[N:51][O:52][N:53]=1>>[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].[F:8][C:9]([F:14])([F:13])[C:10]([OH:12])=[O:11].[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].[NH2:48][C:49]1[C:50]([C:54]([N:43]2[CH2:44][CH2:45][CH:40]([CH2:39][C:38]([NH:37][C:29]3[CH:30]=[CH:31][C:32]4[NH:33][C:34]5[N:35]=[C:19]([NH:20][C:21]6[CH:22]=[N:23][CH:24]=[C:25]([CH:47]=6)[CH2:26][CH2:27][C:28]=3[CH:36]=4)[N:18]=[CH:17][C:16]=5[Cl:15])=[O:46])[CH2:41][CH2:42]2)=[O:55])=[N:51][O:52][N:53]=1

참가 물질

3

반응물 2

HCID 5474544-Amino-1,2,5-oxadiazole-3-carboxylic acidHCID 86636208N-[6-chloro-2,4,8,18,22-pentaazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaen-12-yl]-2-piperidin-4-ylacetamide bis(trifluoroacetate)

생성물 1

HCID 86636215HCID 86636215, 화합물수율 41%

실험 절차

The desired compound was prepared according to the procedure of Example A27, using N-[6-chloro-2,4,8,18,22-pentaazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaen-12-yl]-2-piperidin-4-ylacetamide bis(trifluoroacetate) and 4-amino-1,2,5-oxadiazole-3-carboxylic acid as starting materials in 41% yield. LCMS for C27H28ClN10O3 (M+H)+: m/z=575.2.

출처 및 근거

ORD 기록
ord-1793ccbb869b4af8b829e71a9298c5bb
출처 데이터셋
uspto-grants-2014_10
특허 번호
US08871753B2

연결된 노트

불러오는 중…